ESSA Pharma to Participate in Two Upcoming Investor Conferences
Get Alerts EPIX Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.
David. R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in one-on-one meetings
Event: Jefferies London Healthcare Conference Format: Fireside Chat Date: Thursday, November 17, 2022 Time: 3:15 p.m. GMT / 10:15 a.m. ET
Event: Piper Sandler 34th Annual Healthcare Conference Format: Fireside Chat Date: Tuesday, November 29, 2022 Time: 4:30 p.m. ET
A live webcast of the Jefferies fireside chat can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-participate-in-two-upcoming-investor-conferences-301673393.html
SOURCE ESSA Pharma Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CIEE Visits Wisconsin Dells to Highlight How BridgeUSA Makes America Safer, Stronger, and More Prosperous
- Wix.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Wix.com Ltd. - WIX
- NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share